07:00 , Jun 15, 2015 |  BioCentury  |  Emerging Company Profile

Freshening the gene pool

Horama S.A.S. is developing two gene therapies that target mutations no other companies are working on as a way of differentiating itself from the growing fraternity of ophthalmic gene therapy companies. The company was founded...
08:00 , Feb 24, 2014 |  BC Week In Review  |  Company News

Oxford BioMedica, Sanofi deal

The companies amended an April 2009 deal to grant Sanofi broadened worldwide rights to StarGen and UshStat for all ocular disease indications in exchange for the return to Oxford of all worldwide rights to EncorStat...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Clinical News

StarGen: Phase I/IIa ongoing

Oxford BioMedica said FDA and France's National Agency for the Safety of Medicine and Health Products (ANSM) agreed to allow the company to resume enrollment in Phase I/IIa trials of StarGen and UshStat and a...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Clinical News

UshStat: Phase I/IIa ongoing

Oxford BioMedica said FDA and France's National Agency for the Safety of Medicine and Health Products (ANSM) agreed to allow the company to resume enrollment in Phase I/IIa trials of StarGen and UshStat and a...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Clinical News

RetinoStat: Phase I ongoing

Oxford BioMedica said FDA and France's National Agency for the Safety of Medicine and Health Products (ANSM) agreed to allow the company to resume enrollment in Phase I/IIa trials of StarGen and UshStat and a...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Clinical News

RetinoStat: Phase I suspended enrollment

Oxford BioMedica suspended enrollment in a Phase I trial of RetinoStat and Phase I/IIa trials of StarGen and UshStat after detecting "very low" concentrations of potential impurities in clinical trial material. The company believes the...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Clinical News

StarGen: Phase I/IIa suspended enrollment

Oxford BioMedica suspended enrollment in a Phase I trial of RetinoStat and Phase I/IIa trials of StarGen and UshStat after detecting "very low" concentrations of potential impurities in clinical trial material. The company believes the...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Clinical News

UshStat: Phase I/IIa suspended enrollment

Oxford BioMedica suspended enrollment in a Phase I trial of RetinoStat and Phase I/IIa trials of StarGen and UshStat after detecting "very low" concentrations of potential impurities in clinical trial material. The company believes the...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Clinical News

UshStat: Phase I/IIa ongoing

Oxford BioMedica said an independent DSMB recommended continuation to the second dose cohort in an open-label, dose-escalation, U.S. Phase I/IIa trial of UshStat after a review of data from 3 patients in the first dose...
07:00 , Jul 9, 2012 |  BC Week In Review  |  Company News

Oxford BioMedica, Sanofi deal

Oxford BioMedica said Sanofi exercised its option under an April 2009 deal to acquire exclusive, worldwide rights to Oxford BioMedica's ocular disease products UshStat and StarGen . Oxford BioMedica will receive a $3 million exercise...